Pramipexole reduces phosphorylation of α-synuclein at serine-129

Journal of Molecular Neuroscience

Volumn 51, Issue 2, 2013, Pages 573-580

  Chau, Kai Yin ^a   Cooper, J Mark ^a   Schapira, Anthony Henry V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Synuclein; Dopamine agonists; Neurodegeneration; Neuroprotection; Parkinson's disease; Phosphorylation; Pramipexole

Indexed keywords

ALPHA SYNUCLEIN; CASEIN KINASE II; DOPAMINE RECEPTOR; PRAMIPEXOLE; SERINE; UBIQUITIN;

ARTICLE; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION;

ALPHA-SYNUCLEIN; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CASEIN KINASE II; CELL LINE, TUMOR; HUMANS; PHOSPHORYLATION; SERINE;

EID: 84885191071     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0030-8     Document Type: Article

References (40)

1. Anderson JP et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739-29752
2. Bodenbach L et al (1994) Recombinant human casein kinase II. A study with the complete set of subunits (alpha, alpha′ and beta), site-directed autophosphorylation mutants and a bicistronically expressed holoenzyme. Eur J Biochem 220:263-273
3. Braak H et al (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
4. Braithwaite SP et al (2012) α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev Neurosci 23:191-198
5. Chau KY et al (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem 110:1005-1013
6. Chaudhuri KR et al (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5:235-245
7. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464-474
8. Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion 9:289-298
9. Devi L, Anandatheerthavarada HK (2010) Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta 1802:11-19
10. Du F, Li R, Huang Y, Li X, Le W (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22:2422-2430
11. Ferrari-Toninelli G et al (2010) Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol 10:2
12. Fox SH et al (2008) Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 7:927-938
13. Fuchs J et al (2008) Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 22:1327-1334
14. Fujiwara H et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160-164
15. Gu M et al (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 91:1075-1081
16. Imamura K et al (2008) Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neurosci Lett 440:97-102
17. Iravani MM et al (2006) Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 96:1315-1321
18. Iravani MM et al (2008) Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol 212:522-531
19. Izumi Y et al (2007) Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol 557:132-140
20. Kakimura J et al (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 417:59-67
21. Kragh CL et al (2009) {alpha}-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284:10211-10222
22. Li C et al (2010) Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem Res 35:1546-1556
23. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369:1-15
24. Machiya Y et al (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 285:40732-40744
25. Mbefo MK et al (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 285:2807-2822
26. Nakamura K et al (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 286:20710-20726
27. Obeso JA et al (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16:653-661
28. Olanow CW et al (2008) Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 64(Suppl 2):S101-S110
29. Presgraves SP et al (2004) Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp Neurol 190:157-170
30. Ross OA et al (2008) Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 63:743-750
31. Schapira AH (2006) Etiology of Parkinson's disease. Neurology 66:S10-S23
32. Schapira AH (2008) Progress in neuroprotection in Parkinson's disease. Eur J Neurol 15(Suppl 1):5-13
33. Schapira AH (2009a) Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 72:S44-S50
34. Schapira AH (2009b) Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 30:41-47
35. Schapira AH et al (2009) Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 16:1090-1099
36. Schapira AH et al (2010) Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord 25:1627-1632
37. Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 6:309-317
38. Sha D et al (2010) Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Hum Mol Genet 19:352-363
39. Wakamatsu M et al (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 85:1819-1825
40. Waxman EA, Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 67:402-416